Clinical, serologic, and immunologic effects of human leukocyte interferon in HBsAg-positive primary hepatocellular carcinoma.
Five patients with hepatitis B surface antigen (HBsAg) positive chronic hepatitis and histologically confirmed primary hepatocellular carcinoma (PHC) were treated with 3 X 10(6) units/day of partially purified human leukocyte interferon intramuscularly for 2 consecutive months. During interferon therapy, one patient had stable disease, while the remaining four patients had progressive disease. Following interferon therapy no changes were noted in the hepatitis B viral markers or in serum alphafetoprotein levels. Data on the effects of human leukocyte interferon on lymphocyte subpopulations and on the cytotoxic activity of peripheral blood mononuclear cells against a hepatitis B surface antigen expressing primary hepatocellular carcinoma cell line are presented.
Nair
P V
PV
Tong
M J
MJ
Kempf
R
R
Co
R
R
Lee
S D
SD
Venturi
C L
CL
D000328:Adult; D001402:B-Lymphocytes / Q000276:immunology; D006528:Carcinoma, Hepatocellular / Q000150:complications / Q000276:immunology / Q000628:therapy*; D003601:Cytotoxicity Tests, Immunologic; D003602:Cytotoxicity, Immunologic; D006509:Hepatitis B / Q000150:complications; D006514:Hepatitis B Surface Antigens / Q000032:analysis*; D006801:Humans; D007370:Interferon Type I / Q000009:adverse effects / Q000627:therapeutic use*; D007958:Leukocyte Count; D008113:Liver Neoplasms / Q000150:complications / Q000276:immunology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011863:Radioimmunoassay; D013601:T-Lymphocytes / Q000276:immunology; D013997:Time Factors
D006514:Hepatitis B Surface Antigens; D007370:Interferon Type I